Skip to content
香港聯合腫瘤中心
  • Cancer diagnosis
    • Physical examination
      • Male/Female physical examination plan
    • Endoscopic examination
    • X-ray
    • Ultrasound examination
    • Laboratory examination
    • Cytological examination
    • Pathological diagnosis
    • Positron emission tomography and computed tomography (PET/CT)
    • Magnetic resonance imaging (MRI)
    • Computed tomography (CT) scan
    • Genetic testing
  • Cancer treatment
    • Information for newly diagnosed patients
    • Surgery
    • Radiotherapy
    • Chemotherapy
      • Side Effect
      • Chemotherapy Instructions
      • cancer cell characteristics, and individual constitution.
    • Gene-directed targeted therapy
    • Targeted therapy
    • Hormone therapy
    • Immunotherapy
    • Hyperbaric oxygen therapy
      • Sudden hearing loss
      • Ischemic stroke / Cerebral stroke
      • Diabetic foot ulcers
      • Applications in oncology
  • Types of cancer
    • What is cancer
    • breast cancer
    • Lung cancer
      • Lung cancer articles and reports
    • colorectal cancer
    • liver cancer
    • stomach cancer
    • prostate cancer
    • thyroid cancer
    • brain cancer
    • nasopharyngeal cancer
    • cervical cancer
    • pancreatic cancer
    • Uterine body cancer
  • Cancer information
    • New cancer drugs
      • Lung cancer drugs
      • Breast cancer drugs
      • Bile duct cancer drugs
      • Liver cancer drugs
      • Bowel cancer drugs
      • Urothelial carcinoma drugs
      • Prostate cancer drugs
    • News report
    • Cancer information video
    • Medical lectures
    • Doctor Q&A
  • Clinical research
  • Contact us
    • Contact methods
    • Doctor Updates
    • Join us
  • 繁
  • En
  • Cancer diagnosis
    • Physical examination
      • Male/Female physical examination plan
    • Endoscopic examination
    • X-ray
    • Ultrasound examination
    • Laboratory examination
    • Cytological examination
    • Pathological diagnosis
    • Positron emission tomography and computed tomography (PET/CT)
    • Magnetic resonance imaging (MRI)
    • Computed tomography (CT) scan
    • Genetic testing
  • Cancer treatment
    • Information for newly diagnosed patients
    • Surgery
    • Radiotherapy
    • Chemotherapy
      • Side Effect
      • Chemotherapy Instructions
      • cancer cell characteristics, and individual constitution.
    • Gene-directed targeted therapy
    • Targeted therapy
    • Hormone therapy
    • Immunotherapy
    • Hyperbaric oxygen therapy
      • Sudden hearing loss
      • Ischemic stroke / Cerebral stroke
      • Diabetic foot ulcers
      • Applications in oncology
  • Types of cancer
    • What is cancer
    • breast cancer
    • Lung cancer
      • Lung cancer articles and reports
    • colorectal cancer
    • liver cancer
    • stomach cancer
    • prostate cancer
    • thyroid cancer
    • brain cancer
    • nasopharyngeal cancer
    • cervical cancer
    • pancreatic cancer
    • Uterine body cancer
  • Cancer information
    • New cancer drugs
      • Lung cancer drugs
      • Breast cancer drugs
      • Bile duct cancer drugs
      • Liver cancer drugs
      • Bowel cancer drugs
      • Urothelial carcinoma drugs
      • Prostate cancer drugs
    • News report
    • Cancer information video
    • Medical lectures
    • Doctor Q&A
  • Clinical research
  • Contact us
    • Contact methods
    • Doctor Updates
    • Join us
  • 繁
  • En

Category: 膽管癌

藥物資訊-美國FDA批準膽管癌靶向新藥infigratinib在中國開發

The U.S. FDA approved the development of infigratinib, a targeted new drug for bile duct cancer, in China

  2021年05月，美國食品和藥物管理局（FDA）已加速批準Truseltiq（infigratinib），用於治療先前接受過治療、攜帶F

立即閱讀
December 15, 2022 No Comments
藥物資訊-膽管癌精準治療藥物Pemigatinib爲患者創造價值

Precision treatment drug Pemigatinib for bile duct cancer creates value for patients

膽管癌（Cholangiocarcinoma，CCA）是一種罕見（大多數國家發病率低於6/100,000）但致死率極高的惡性腫瘤。局部晚期和轉移性膽管

立即閱讀
November 8, 2022 No Comments
藥物資訊-IDH1突變膽管癌精準治療！靶向藥Tibsovo獲FDA批準新適應癥

Precise treatment of IDH1 mutant bile duct cancer! Targeted drug Tibsovo approved by FDA for new indications

膽管癌是一種高異質性、具有侵襲性的癌癥，其中約有13%的患者存在IDH1突變，IDH1是一種代謝酶，當其發生突變時，可以阻斷細胞正常分化，并促進細胞迅

立即閱讀
June 21, 2022 No Comments
藥物資訊-依維替尼(TIBSOVO)可改善膽管癌患者的疾病進展生存期？

Can IVETINIB (TIBSOVO) improve the survival of disease progression in patients with bile duct cancer?

目前膽管癌的致病因素尚不明確，但大量研究表明，膽管癌的發生與以下因素有關：膽管結石的患者，結石長期刺激誘發膽管癌變；先天性膽道發育異常，比如膽管擴張症

立即閱讀
June 21, 2022 No Comments
藥物資訊-膽管癌控制率超80%！ FGFR靶向藥Truseltiq有效延長生存期

Over 80% control rate for bile duct cancer! FGFR-targeted drug Truseltiq effectively prolongs survival.

膽管癌控制率超80%！ FGFR靶向藥Truseltiq有效延長生存期 近年來膽管癌的發病率逐年升高，手術是唯一具有治愈潛力的治療方式。但是大部分膽管

立即閱讀
June 15, 2022 No Comments
藥物資訊-膽管癌再迎重磅新藥！Truseltiq獲FDA加速批準上市

Another blockbuster drug for bile duct cancer! Truseltiq receives accelerated approval from the FDA.

膽管癌患者大多數發現時已經處於晚期，加之缺乏有效的治療，5年生存率非常低。研究發現，FGFR2基因變異存在於大約15%到20%的肝內膽管癌患者中。近日

立即閱讀
June 9, 2022 No Comments
藥物資訊-膽管癌新一代FGFR抑制劑登場！Gunagratinib獲授FDA孤兒藥稱號

A new generation of FGFR inhibitors for cholangiocarcinoma has arrived! Gunagratinib has been granted FDA orphan drug designation.

 膽管癌新一代FGFR抑制劑登場！Gunagratinib獲授FDA孤兒藥稱號 FGFR是肝內膽管癌最常見的突變類型之一，其中FGFR1/2/3突變在

立即閱讀
June 9, 2022 No Comments
藥物資訊-膽管癌控制率超80%！FGFR靶向藥Truseltiq有效延長生存期

Over 80% control rate for bile duct cancer! FGFR-targeted drug Truseltiq effectively prolongs survival.

近年來膽管癌的發病率逐年升高，手術是唯一具有治愈潛力的治療方式。但是大部分膽管癌患者在初診時即爲不可切除性腫瘤或存在轉移，失去了手術根治的機會。抗癌新

立即閱讀
June 8, 2022 No Comments
藥物資訊-膽管癌轉移還能活多久？靶向新藥Pemigatinib生存率出人意料

How long can bile duct cancer metastasis last? The survival rate of the targeted new drug Pemigatinib is unexpected

膽管癌雖然是一種少見的癌癥，但是近年來有不斷上升的趨勢。FGFR2基因融合或重排幾乎僅發生於肝內膽管癌(iCCA)，其中10% ~ 16%的患者存在這

立即閱讀
June 8, 2022 No Comments
藥物資訊-膽管癌再迎靶向新藥！IDH1抑制劑Ivosidenib顯著降低死亡風險

Another new targeted drug for cholangiocarcinoma! IDH1 inhibitor Ivosidenib significantly reduces the risk of death.

膽管癌再迎靶向新藥！IDH1抑制劑Ivosidenib顯著降低死亡風險 肝內膽管癌是一種非常具有侵襲性的癌癥，其預後差，5年生存率低於10%，對於無法

立即閱讀
June 8, 2022 No Comments
Page1 Page2
香港聯合腫瘤中心

The Hong Kong United Oncology Centre (HKUOC) provides cancer-related medical services such as cancer screening, cancer diagnosis and cancer treatment, including immunotherapy, chemotherapy, targeted drug therapy, radiation therapy, hormone therapy and palliative care.

Contact us

  • Address: Rooms 01-06, 20/F, 238 Nathan Road, Kowloon (MTR Jordan Station Exit E)
  • Phone: +852 2386 8002
  • WhatsApp：5518 2992
  • Fax: (852) 2386 8229
  • Macau: Enquiry@hkuoc.hk

Consultation time

Monday to Friday

9:00 am to 1:00 pm

2:00 p.m. to 6:00 p.m.

Saturday

9:00 am to 1:00 pm

Closed on Sundays and public holidays

Types of cancer

  • breast cancer
  • Lung cancer
  • colorectal cancer
  • liver cancer
  • stomach cancer
  • prostate cancer
  • thyroid cancer
  • brain cancer
  • nasopharyngeal cancer
  • pancreatic cancer
  • Uterine body cancer
  • breast cancer
  • Lung cancer
  • colorectal cancer
  • liver cancer
  • stomach cancer
  • prostate cancer
  • thyroid cancer
  • brain cancer
  • nasopharyngeal cancer
  • pancreatic cancer
  • Uterine body cancer

Cancer treatment

  • Information for newly diagnosed patients
  • Surgery
  • Radiation therapy (electrotherapy)
  • Chemotherapy
  • Targeted therapy
  • Hormone therapy
  • Immunotherapy
  • Information for newly diagnosed patients
  • Surgery
  • Radiation therapy (electrotherapy)
  • Chemotherapy
  • Targeted therapy
  • Hormone therapy
  • Immunotherapy

phone

WhatsApp

Facebook